Gurbel PA - Search Results

1

The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.

Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, Angiolillo DJ, Nolin TD, Maa JF, Bailey WL, Jakubowski JA, Ojeh CK, Jeong YH, Tantry US, Baker BA. Gurbel PA, et al. J Am Coll Cardiol. 2013 Aug 6;62(6):505-12. doi: 10.1016/j.jacc.2013.03.037. Epub 2013 Apr 16. J Am Coll Cardiol. 2013. PMID: 23602770 Free article. Clinical Trial.

2

Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation.

Gurbel PA, Malinin AI, Callahan KP, Serebruany VL, O'Connor CM. Gurbel PA, et al. Am J Cardiol. 2002 Aug 1;90(3):312-5. doi: 10.1016/s0002-9149(02)02471-2. Am J Cardiol. 2002. PMID: 12127620 No abstract available.

3

Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study.

Gurbel PA, Callahan KP, Malinin AI, Serebruany VL, Gillis J. Gurbel PA, et al. J Invasive Cardiol. 2002 Oct;14(10):584-9. J Invasive Cardiol. 2002. PMID: 12368510 Clinical Trial.

4

Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.

Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL; Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Gurbel PA, et al. Am Heart J. 2003 Feb;145(2):239-47. doi: 10.1067/mhj.2003.109. Am Heart J. 2003. PMID: 12595840

5

Durability of platelet inhibition by clopidogrel.

Gurbel PA, Bliden KP. Gurbel PA, et al. Am J Cardiol. 2003 May 1;91(9):1123-5. doi: 10.1016/s0002-9149(03)00163-2. Am J Cardiol. 2003. PMID: 12714161 Clinical Trial. No abstract available.

6

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.

Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Gurbel PA, et al. Circulation. 2003 Jun 17;107(23):2908-13. doi: 10.1161/01.CIR.0000072771.11429.83. Epub 2003 Jun 9. Circulation. 2003. PMID: 12796140 Clinical Trial.

7

Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).

Serebruany VL, Malinin AI, O'connor CM, Gurbel PA; Roxifiban Oral Compound Kinetics Evaluation Trial-I Platelet Substudy. Serebruany VL, et al. Among authors: gurbel pa. Am Heart J. 2003 Jul;146(1):91-8. doi: 10.1016/S0002-8703(03)00186-8. Am Heart J. 2003. PMID: 12851613 Clinical Trial.

8

Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy).

Gurbel PA, Galbut B, Bliden KP, Bahr RD, Roe MT, Serebruany VL, Gibler WB, Christenson RH, Ohman EM; EARLY Platelet Substudy. Gurbel PA, et al. J Thromb Thrombolysis. 2002 Dec;14(3):213-9. doi: 10.1023/a:1025048726396. J Thromb Thrombolysis. 2002. PMID: 12913401 Clinical Trial.

9

Platelet activation after stenting with heparin-coated versus noncoated stents.

Gurbel PA, Bliden KP. Gurbel PA, et al. Am Heart J. 2003 Oct;146(4):E10. doi: 10.1016/S0002-8703(03)00317-X. Am Heart J. 2003. PMID: 14564333 Clinical Trial.

10

A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity.

Gurbel PA, Bliden KP. Gurbel PA, et al. Platelets. 2003 Nov-Dec;14(7-8):481-3. doi: 10.1080/02697450310001632588. Platelets. 2003. PMID: 14713517 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

492 results

Search Page